NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of SRC Energy Inc. (NYSE: SRCI), Pivotal Software, Inc. (NYSE: PVTL), MAM Software Group, Inc. (NASDAQ: MAMS), and Fibrocell Science, Inc. (NASDAQ: FCSC). Additional information about each potential action can be found at the link provided.
SRC Energy Inc. (NYSE: SRCI)
Buyer: PDC Energy, Inc.
Pursuant to the proposed transaction, announced on August 26, 2019 and valued at $1.7 billion, SRC shareholders will receive 0.158 shares of PDC common stock for each share of SRC common stock owned. The investigation focuses on whether SRC and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
To learn more about the SRC investigation go to: https://bespc.com/srci/.
Pivotal Software, Inc. (NYSE: PVTL)
Buyer: VMware, Inc.
Pursuant to the proposed transaction, announced on August 22, 2019 and valued at $2.7 billion, Pivotal shareholders of Class A common stock will receive $15 in cash for each share of Pivotal Class A common stock owned. In addition, Pivotal Class B common stock held by Dell Technologies will be exchanged for 0.0550 shares of VMware Class B common stock. The investigation focuses on whether Pivotal and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
To learn more about the Pivotal investigation go to: https://bespc.com/pvtl2/.
MAM Software Group, Inc. (NASDAQ: MAMS)
Buyer: Kerridge Commercial Systems
Pursuant to the proposed transaction, announced on September 3, 2019 and valued at $154.2 million, MAM shareholders will receive $12.12 in cash for each share of MAM common stock owned. The investigation focuses on whether MAM and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
To learn more about the MAM investigation go to: https://bespc.com/mams/.
Fibrocell Science, Inc. (NASDAQ: FCSC)
Buyer: Castle Creek Pharmaceutical Holdings
Pursuant to the proposed transaction, announced on September 12, 2019 and valued at $63.3 million, Fibrocell shareholders will receive $3 in cash for each share of Fibrocell common stock owned. The investigation focuses on whether Fibrocell and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
To learn more about the Fibrocell investigation go to: https://bespc.com/fcsc/.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Alexandra Raymond, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com